To meet the growing global demand for respiratory active pharmaceutical ingredients (APIs), Inke is to invest €9 million into its production plant to reinforce focus on inhalation micronised APIs
The facility will support clinical development by securing supply that will address the critical demand in the gene therapy and vaccine markets
Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies
This marks an expansion of the companies' existing collaboration and further validates the use of Albumedix Recombumin rHA products in the manufacturing process and final formulation of critical vaccines
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
This partnership allows both companies to become first movers to bridge an inevitable gap with the largest organizations in the pharmaceutical, nutraceutical, cosmetic, and veterinary sectors
Rodolfo brings with him a wealth of rich experience from commercial, marketing, and general management roles across several multinational companies
This product will be manufactured at Lupin’s Nagpur facility in India
Through the contract, the company will supply two key GMP intermediates for one of the 'patented drugs' of the innovator pharmaceutical customer
The product will be manufactured at Lupin’s facility in Goa, India
Subscribe To Our Newsletter & Stay Updated
